Sven Pålhagen

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. doi request reprint Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease
    S E Palhagen
    Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
    Acta Neurol Scand 126:e29-33. 2012
  2. ncbi request reprint Selegiline slows the progression of the symptoms of Parkinson disease
    S Palhagen
    Department of Neurology, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Neurology 66:1200-6. 2006
  3. doi request reprint Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
    S E Palhagen
    Department of Clinical Neuroscience, Division of Neurology Huddinge, Karolinska Institute, Stockholm, Sweden
    Acta Neurol Scand 117:295-304. 2008
  4. doi request reprint HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment
    Sven E Pålhagen
    Department of Clinical Neuroscience, Division of Neurology Huddinge, Karolinska Institute, Stockholm, Sweden
    J Neurol 256:1510-8. 2009
  5. doi request reprint Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression
    Sven Pålhagen
    Section of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
    J Neurol 257:524-32. 2010
  6. doi request reprint Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease
    Ingemar Bjorkhem
    Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden Electronic address
    Neurosci Lett 555:102-5. 2013

Detail Information

Publications6

  1. doi request reprint Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease
    S E Palhagen
    Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
    Acta Neurol Scand 126:e29-33. 2012
    ..The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care...
  2. ncbi request reprint Selegiline slows the progression of the symptoms of Parkinson disease
    S Palhagen
    Department of Neurology, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Neurology 66:1200-6. 2006
    ..To study the long-term effects of selegiline in monotherapy and in combination with levodopa in the early phase of Parkinson disease (PD)...
  3. doi request reprint Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
    S E Palhagen
    Department of Clinical Neuroscience, Division of Neurology Huddinge, Karolinska Institute, Stockholm, Sweden
    Acta Neurol Scand 117:295-304. 2008
    ....
  4. doi request reprint HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment
    Sven E Pålhagen
    Department of Clinical Neuroscience, Division of Neurology Huddinge, Karolinska Institute, Stockholm, Sweden
    J Neurol 256:1510-8. 2009
    ..These observations support our hypothesis that PD combined with MD is an expression of a more advanced and widespread neurodegenerative disorder...
  5. doi request reprint Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression
    Sven Pålhagen
    Section of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
    J Neurol 257:524-32. 2010
    ..Thus, the biochemical basis and the response to citalopram differ between PD patients with MD and patients with solely MD...
  6. doi request reprint Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease
    Ingemar Bjorkhem
    Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden Electronic address
    Neurosci Lett 555:102-5. 2013
    ..There was no correlation between levels of 27-OH in CSF and duration of the disease. These data indicates that oxysterol levels in CSF may be of value to follow disease progression. ..